What is COGT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.38B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for COGT?

P/E (TTM) is n/a and 52-week range is $13.78 to $43.73 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s COGT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for COGT?

The company profile lists revenue (TTM) near $23M, net income (TTM) near $-6.12B, EPS (TTM) near $-2.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cogent Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 170.9M shares outstanding, ISIN US19240Q2012 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cogent Biosciences Inc

$COGT

Health Care · Biotechnology

IR Run Scenarios

$31.00

+3.06%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Employees

258

Website

www.cogentbio.com/

IPO

2018-03-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)